JTJillian Theobald

Jillian Theobald

*This is an algorithmically generated author record based on publicly available information.

Jillian Theobald has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A 25-Year Analysis of Muscarinic Mushroom Poisoning in Wisconsin

    by Ryan Feldman, Megan Audette, Jamie Sterr, Madelyn Lechmaier, Jillian Theobald

  • Outcomes of benzonatate exposures reported to a single United States poison center: a 20-year review

    by Corey D. Cicci, Jillian Theobald, Matthew Stanton, Ryan Feldman

    Benzonatate is an antitussive with sodium channel blocking properties that may cause seizures, dysrhythmias, and death in overdose. Limited data describe the medical outcomes of benzonatate exposures, and no standard treatment guidelines exist for managing benzonatate toxicity. We characterized clinical outcomes and management of benzonatate exposures over a 20-year period at the Wisconsin Poison Center. This retrospective case review examined all benzonatate exposures reported to a single regional poison center from January 1, 2000 through December 31, 2019. Exposures were excluded if the medical record was incomplete. The primary outcome was the rate of serious adverse effects, defined as seizure, electrocardiogram changes, coma or central nervous system depression, or death. Potential life-saving treatments (antiepileptics, antidysrhythmics, vasopressors, sodium bicarbonate, or intravenous lipid therapy) were also assessed. A total of 313 calls were received with 48 exposures excluded, leaving 265 exposures included for analysis. Most exposures were female (162/265; 61%) with a median age of 19 years (IQR: 4-39 years). Sixteen exposures were adverse reactions only. Of intentional exposures (106/265; 40%), 23 (22%) experienced at least one serious adverse effect and 40 (38%) were hospitalized. Of unintentional exposures (143/265, 54%), one (0.7%) experienced a serious adverse effect and three (2%) were hospitalized. Regarding 77 unintentional pediatric exposures, none experienced a serious adverse effect, with two (2/77; 3%) hospitalized. Two deaths (0.8%) occurred during the study period; both were intentional exposures. While severe outcomes are possible after intentional exposures, unintentional exposures rarely exhibited serious toxicities. No therapeutic interventions beyond supportive care were consistently employed. Intentional exposures to benzonatate more commonly warranted significant therapeutic interventions and caused a higher incidence of serious toxicity. Unintentional exposures did not result in clinically significant adverse effects. Although benzonatate can result in serious toxicity, adults with unintentional exposures may be candidates for home management.


  • Trimeresurus insularis (blue Indonesian pit viper) envenomation treated with Thai green pit viper antivenom

    by Ryan Feldman, Matthew Stanton, Justin Corcoran, Kristin Bialkowski, Jillian Theobald, David Gummin


  • A systematic review of phenibut withdrawal focusing on complications, therapeutic approaches, and single substance versus polysubstance withdrawal

    by Ryan Feldman, Brian Autry, Joanna Dukes, Thomas Lofy, Gina Marchetti, Amber Patt, Nicole Batterman, Jillian Theobald

    Phenibut is an unregulated supplement that acts primarily as a gamma-aminobutyric acid type B receptor agonist. Use of phenibut can lead to dependence and subsequent withdrawal when use is stopped. Phenibut withdrawal can cause severe symptoms such as delirium, hallucinations, and seizures. The purpose of this systematic review is to characterize the natural history of phenibut withdrawal and summarize treatment strategies published in the literature. A systematic review was conducted using the preferred reporting items for systematic reviews and meta-analyses checklist. English language peer-reviewed articles or conference abstracts in humans describing phenibut withdrawal after cessation of use were included. Databases (Ovid/MEDLINE, Web of Science, and Science Direct) and references of included articles were searched. Case reports were appraised using the Joanna Briggs Institute critical appraisal checklist for case reports. Patient demographics and key outcomes, including withdrawal characteristics and treatment characteristics, were collected into a predefined data collection sheet by six independent reviewers. Search results yielded 515 articles of which 25 were included. All articles were case reports or published conference abstracts. All of the cases (100 percent) involved male patients and the median age was 30 years, (interquartile range 23.5-34 years, range 4 days-68 years). The median daily phenibut dose prior to experiencing withdrawal was 10 g (interquartile range 4.75-21.5 g, range 1-200 g). The shortest duration of phenibut use (2-3 g daily) prior to withdrawal was one week. Withdrawal symptoms occurred as quickly as two hours after the last phenibut dose. Sixteen patients (64 percent) reported progression of withdrawal severity within the first 24 hours of healthcare contact. Seizures were reported in two patients (8 percent), intubation in six patients (24 percent), and intensive care unit admission in 11 patients (44 percent). Withdrawal patterns and outcomes were similar in those using phenibut alone and those with comorbid polysubstance use. Withdrawal treatment strategies varied widely. Only three cases (12 percent) were managed outpatient and all three utilized a phenibut tapering strategy. All patients undergoing medication-assisted abstinence were admitted inpatient for symptom management and received a drug that acts on gamma-aminobutyric acid receptors. The most commonly used medication was a benzodiazepine, reported in 17 cases (68 percent). Nineteen patients (76 percent) required at least two drug therapies to manage symptoms. Baclofen was used in 15 cases (60 percent), primarily in conjunction with gamma-aminobutyric acid type A agonists (12 of 15 cases) or as monotherapy during a phenibut taper (two of 15 cases). Two patients using baclofen monotherapy outpatient, after initial stabilization with multiple drug classes, reported adverse effects. One patient had a seizure and the other experienced recurrent withdrawal symptoms, returned to using phenibut, and was admitted to a hospital for withdrawal symptom management with benzodiazepines. This review is subject to several limitations. Due to the manual nature of article selection, it is possible relevant articles may not have been included. As the entire data set is comprised of case reports it may suffer from publications bias. Outcomes and meaningful conclusions from specific treatment strategies were rarely available because of the heterogeneous nature of case reports. It is possible those reporting only phenibut use were actually using multiple substances. The doses of phenibut a user believed they were taking may be different from what was present in the unregulated product. Phenibut withdrawal appears to have a range of severity. It is important to recognize that patients undergoing phenibut abstinence may have progressive symptom worsening during early withdrawal. All published cases of abrupt phenibut abstinence were admitted inpatients for symptom management. Benzodiazepines or barbiturates with adjunctive baclofen appear to be the most commonly used drugs for moderate to severe withdrawal. Outpatient management via slow phenibut tapers with or without adjunctive gamma-aminobutyric acid agonist therapy may be successful. However, there is no standard treatment, and consultation with experts (e.g., toxicologists, addiction specialists) experienced in managing withdrawal syndromes is recommended. Significant study is warranted to develop methods of triaging phenibut withdrawal (e.g., severity scoring, inpatient versus outpatient management) and creating optimal treatment regimens.


  • Outcomes of pediatric ingestions of alcohol-based hand sanitizers during the COVID-19 pandemic

    by Justin Corcoran, Ryan Feldman, Jillian Theobald

    In July 2020, an outbreak of methanol-contaminated hand sanitizers in the United States prompted our regional poison center to implement a more conservative triage guideline for hand sanitizer exposures. All pediatric hand sanitizer ingestions of more than a "taste" were referred to a healthcare facility for assessment. We then evaluated the effect of this change on identifying patients with methanol poisoning. This was a single-center, retrospective review of pediatric (<19 years) hand sanitizer ingestions reported to our poison center from May 1, 2020 through January 28, 2022. Methanol and ethanol concentrations were collected if available. During the study period, we received 801 calls regarding hand sanitizer exposure, of which 140 children were referred to a healthcare facility for hand sanitizer ingestions. Of those, 88 (63%) had methanol and/or ethanol concentrations measured. No child had a detectable methanol concentration, 78 had ethanol testing, and 12 had a detectable ethanol concentration. In this sample, no patient tested had a detectable methanol concentration. Children who consumed enough to have a detectable ethanol concentration were symptomatic or had an intentional ingestion. Asymptomatic children with unintentional ingestion of hand sanitizer were at low risk for methanol toxicity.


  • Incidence of rebound salicylate toxicity following cessation of urine alkalinization

    by Mary O’kEefe, Matthew Stanton, Ryan Feldman, Jillian Theobald

    Management of patients with salicylate toxicity frequently requires urine alkalinization to enhance excretion of salicylate. One strategy for determining when to stop urine alkalinization is to wait for two consecutive serum salicylate concentrations to be less than 300 mg/L (2.17 mmol/L) and declining. When alkalinization of the urine ceases, a rebound in serum salicylate concentration can occur from tissue redistribution or delayed gastrointestinal absorption. Whether this can lead to rebound toxicity is not well understood. This was a single-center, retrospective review of cases with a primary ingestion of acetylsalicylic acid reported to the local poison center over a five-year period. Cases were excluded if the product was not listed as the primary ingestion or if there was no serum salicylate concentration documented after discontinuation of intravenous sodium bicarbonate infusion. The primary outcome was the incidence of serum salicylate rebound to a concentration greater than 300 mg/L (2.17 mmol/L) after discontinuation of intravenous sodium bicarbonate infusion. A total of 377 cases were included. Of these, eight (2.1%) had a serum salicylate concentration increase (rebound) after stopping the sodium bicarbonate infusion. All these cases were acute ingestions. Five of the eight cases had rebound serum salicylate concentrations that were greater than 300 mg/L (2.17 mmol/L). Of these five patients, only one reported recurrent symptoms (tinnitus). Prior to stopping urinary alkalinization, the last or the last two serum salicylate concentrations were less than 300 mg/L (2.17 mmol/L) in three and two cases, respectively. In patients with salicylate toxicity, the incidence of rebound in serum salicylate concentration after cessation of urine alkalinization, is low. Even if serum salicylate rebounds to supratherapeutic concentrations, symptoms are often absent or mild. Routine repeat serum salicylate concentrations after urine alkalinization is stopped may be unnecessary unless symptoms recrudesce.


  • QTc Prolongation in Poison Center Exposures to CredibleMeds List of Substances with “Known Risk of Torsades de Pointes”

    by Kaitlin Ryan, Paul Benz, Amy Zosel, Andrew Farkas, Jillian Theobald

    Many drugs carry some risk of QT interval prolongation, which can lead to life-threatening dysrhythmias including Torsades de Pointes (TdP). CredibleMeds.org identifies medications categorized as “Known Risk of TdP” but does not stratify risk in acute supratherapeutic ingestions. We sought to determine the proportion of cases exhibiting QTc prolongation and life-threatening dysrhythmias including ventricular tachycardia (VT)/ventricular fibrillation (VF), TdP, and asystole in patients exposed to these substances. Retrospective chart review of cases reported to our Regional Poison Center from 2014 to 2019 of exposures to one or more of the “Known Risk” substances was performed. Demographics, therapies, clinical effects, and medical outcome for each case were analyzed. There were 1125 exposures, of which 760 had a documented QTc interval. QTc ≥ 500 ms was reported in 138 (18.2%) of the 760 cases. The most common “Known Risk” substances were citalopram, escitalopram and cocaine. Although not in the “Known Risk” category, mirtazapine, amitriptyline, diphenhydramine, and trazodone had a statistically significant association with QTc > 500 ms. Life-threatening dysrhythmias occurred in 13 cases, with VT/VF in 6 of the 760 (0.8%) cases, and one case of TdP. Flecainide (OR 11.1, 95% CI 2.2–55.8) and methadone (OR 7.1, 95% CI 2.1–23.4) were associated with increased risk of all life-threatening dysrhythmias. Exposures to medications on the Credible Meds list of “Known Risk of TdP” QTc prolongation is common, but life-threatening dysrhythmias are rare. Mirtazapine, amitriptyline, diphenhydramine, and trazodone were associated with prolonged QTc. Flecainide and methadone had the highest associated risk of life-threatening dysrhythmias.


  • Trioxane Ingestion in a Child

    by Jillian L. Theobald, Mark Kostic, Matthew Stanton, David Gummin

    Trioxane is a stable cyclic trimer of formaldehyde. It is an active ingredient in fuel bars for heating prepackaged foods by military and outdoorspeople. Trioxane depolymerizes to formaldehyde in an acidic environment and is further oxidized to formic acid, which causes neurologic and ocular damage. Because it is solid at room temperature, trioxane is a greater potential hazard to children than aqueous formaldehyde. Little information is available regarding the management of ingestion of solid, compressed fuel bars. We present a case of a 19-mo-old male child who ingested an unknown amount of a trioxane fuel bar, with fortunately limited consequences.

  • Complications from Needle Thoracostomy: Penetration of the Myocardium

    by Arielle Thomas, K. Hope Wilkinson, Kevin Young, Timothy Lenz, Jillian Theobald

    We report a rare but serious complication of needle thoracostomy, penetration of the myocardium. Needle thoracostomy is typically performed in the prehospital setting or upon arrival in the emergency department for suspected tension pneumothorax. Needle decompression is generally taught and done anteriorly, in the 2nd intercostal space on the midclavicular line (MCL). An alternative approach is laterally, along the anterior axillary line (AAL) in the 4th intercostal space. Our case supports prior literature that the anterior MCL location has a low rate of efficacy to decompress the chest, as well as a high rate of complications. We recommend performing needle decompression laterally at the AAL whether in the field or in the emergency department.


  • Carbon monoxide detector effectiveness in reducing poisoning, Wisconsin 2014–2016

    by Grace M. Christensen, Paul D. Creswell, Jillian Theobald, Jon G. Meiman

    Introduction: Carbon monoxide (CO) is a colorless, odorless, and nonirritating gas. The most common exposures are from gas powered appliances such as furnaces, water heaters, stoves, and vehicles. To prevent poisoning, CO detectors with audible alarms were developed. This study aims to evaluate the effectiveness of CO detectors in reducing poisoning in Wisconsin. Methods: Records were queried from National Poison Data System for unintentional CO exposures that occurred in residences in Wisconsin during 2014–2016 (N = 703). After applying sample exclusion criteria, notes were abstracted for cases where CO detector use was mentioned (n = 408). Logistic regression analyses were used to assess the association between having a CO detector alarm and CO poisoning. Linear regression analyses were used to assess the relationship between having a CO detector alarm and poisoning severity. Results: In logistic models, odds of CO poisoning were 3.2 times higher (95% CI: 1.5, 6.9) among those who had no CO detector compared to those who had a CO detector that alarmed. In linear models, not having a CO detector was associated with a 0.34 point (95% CI: 0.17, 0.54) change in outcome severity score compared to having a CO detector that alarmed. Discussion: Individuals who were exposed to CO in the absence of a CO detector were more likely to be poisoned and to have more severe medical outcomes than those that had a CO detector that alarmed.